サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1736635

核医学市場：タイプ別、用途別、エンドユーザー別、地域別、2026～2032年

Nuclear Medicine Market By Type, Application End-Users, Region for 2026-2032

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.83円
核医学市場：タイプ別、用途別、エンドユーザー別、地域別、2026～2032年
出版日: 2025年05月05日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

核医学市場の評価、2026～2032年

心血管疾患、がん、呼吸器疾患、神経疾患、代謝性疾患などの慢性疾患の有病率の増加は、核医学市場の重要な促進要因です。したがって、慢性疾患の有病率の増加は、市場規模の成長を急増させ、2024年には68億米ドルを突破し、2032年には129億9,000万米ドルの評価額に達します。

ヘルスケア分野での核医学の採用は、従来の医薬品に比べ初期段階にありました。しかし、医療用画像処理技術、放射性医薬品の進歩、核医学の利点に対する理解の深まりにより、核医学の採用が増加しています。このように、ヘルスケア分野における核医学の採用拡大により、市場は2026～2032年にかけてCAGR 9.30％で成長します。

核医学市場の定義/概要

核医学は、神経学、循環器学、内分泌系、消化器系、がんなどのさまざまな疾患の診断と治療に放射性物質、すなわち放射性医薬品を利用する学際的な分野です。放射性医薬品には放射性トレーサーが含まれており、患者の体内に注入されるとガンマ線を放出します。これらの放射線は、単一光子放射断層撮影法（SPECT）や陽電子放射断層撮影法（PET）のような高度な画像技術によって捕捉され、従来のイメージング法の能力を凌駕する、疾患の早期発見、正確な診断、総合的な検査に役立つ非常に詳細な画像を可能にします。

最近の放射性医薬品の進歩により、がん細胞の増殖、心臓疾患における心筋灌流、重症肺炎における換気、甲状腺機能亢進症における甲状腺や副甲状腺の活動など、ミクロレベルの生理学的プロセスを研究する能力が向上しています。核医学は、抗体、生物学的薬剤、ペプチドとの放射性医薬品結合体を含む次世代治療の研究開発において、ますます利用されるようになっています。これにより、標的ドラッグデリバリー、投与量の最適化、革新的な治療ソリューションの創出が可能になります。その結果、核医学は強力な診断ツールであるだけでなく、さまざまな医療分野で治療戦略を進める上で重要な役割を担っています。

がんと心血管疾患の罹患率の増加は、どのように核医学市場の成長を急増させるのか？

世界保健機関（WHO）によると、がんは世界の主要死因であり、2020年には約1,000万人が死亡するとされています。米国心臓協会（American Heart Association）の報告によると、心血管系疾患は世界の主要な死因であり、2019年には年間1,790万人以上の死亡を占めました。放射性医薬品と画像診断装置の技術的進歩Verified Market Researchによると、放射性医薬品市場は2023年に60億5,000万米ドルと評価され、2032年には136億1,000万米ドルに達し、CAGRは11.76%成長すると予測されています。

核医学研究開発への投資が増加しています。米国エネルギー省科学局の核物理学研究予算は、2021会計年度で7億1,300万米ドルでした。欧州委員会は、Euratom Research and Training Programme 2021-2025の下、核研究と訓練活動に13億8,000万ユーロを割り当てました。個別化医療に対する認識と受容の高まりVerified Market Researchの報告書によると、個別化医療市場は2023年に1,302億3,000万米ドル、2032年には2,725億9,000万米ドルに成長し、2026～2032年までのCAGRは10.67%になると予測されています。個別化医療連合（Personalized Medicine Coalition）の調査によると、がん専門医の73％ががん患者に個別化医療検査を利用しています。

分子イメージングにおける放射性同位元素の応用が拡大しています。米国原子力規制委員会の報告によると、米国では毎年約5,000万件の核医学検査が行われています。高齢者人口の増加とそれに伴う慢性疾患の増加が主な要因です。国連は、65歳以上の世界人口が他のすべての年齢層よりも急速に増加しており、2050年までに15億人に倍増すると予測していると報告しました。WHOは、2030年までに世界の6人に1人が60歳以上になり、診断および治療用核医学処置の需要が増加すると予測しています。

核医学手技と装置の高コストは核医学市場の成長をどのように阻害するか？

核医学検査と装置のコストが高いことが核医学市場の成長を妨げています。米国放射線学会（American College of Radiology）によると、米国におけるPET/CTスキャンの平均費用は1,250～1,650ドルであり、多くの患者にとって法外に高額です。厳しい規制要件もあります。米国原子力規制委員会は、新しい放射性医薬品の審査と承認に平均24ヶ月かかると報告しています。欧州では、欧州医薬品庁（EMA）が2018～2022年の間に承認した新規放射性医薬品はわずか3品目であり、承認プロセスの厳しさが浮き彫りになっています。

核医学・分子イメージング学会は、テクネチウム-99mのような一般的に使用される放射性同位元素の半減期はわずか6時間であり、物流を複雑にし、コストを増大させていると指摘しました。Journal of Nuclear Medicine誌に掲載された研究によると、半減期の短い放射性医薬品は、物流の課題により、準備された投与量の最大20％が未使用となっています。熟練した核医学技師の不足もあります。米国労働統計局は、2019～2029年にかけて核医学検査技師の需要が5％増加すると予測しましたが、この分野は小規模であり、2019年の求人数は約1万8,000件に過ぎないと指摘しました。米国放射線技師会の調査によると、2019年には核医学検査技師の4.7％が欠員となっており、有資格者が不足していることを示しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション
  • 調査スケジュール
  • 前提条件
  • 制限事項

第2章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • データの三角測量
  • ボトムアップアプローチ
  • トップダウンアプローチ
  • リサーチフロー
  • 業界専門家による主要な洞察
  • データソース

第3章 エグゼクティブサマリー

  • 市場概要
  • エコロジーのマッピング
  • 絶対的収益機会
  • 市場の魅力
  • 核医学の世界市場：地域別
  • 核医学の世界市場：タイプ別
  • 核医学の世界市場：用途別
  • 核医学の世界市場：エンドユーザー別
  • 今後の市場機会
  • 世界市場分割
  • 製品ライフライン

第4章 市場概要

  • 世界の核医学の進化
  • 促進要因
  • 抑制要因
  • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析
  • 価格分析
  • マクロ経済分析

第5章 核医学市場：タイプ別

  • 概要
  • 診断用核医学
  • PET放射性医薬品
  • SPECT放射性医薬品
  • 治療用核医学

第6章 核医学市場：用途別

  • 概要
  • 腫瘍学
  • 神経学
  • 循環器

第7章 核医学市場：エンドユーザー別

  • 概要
  • 病院および診療所
  • 診断センター

第8章 核医学市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ
  • 中東・アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な発展
  • 企業の地域フットプリント
  • 企業の業界フットプリント
  • ACEマトリックス

第10章 企業プロファイル

  • GE Healthcare
  • Curium Pharma
  • Novartis
  • Cardinal Health
  • Lantheus Medical Imaging
  • Jubilant Life Sciences Ltd
  • Nordion Inc.
  • Bracco Imaging S.P.A
  • The Institute for Radioelements（IRE）
  • NTP Radioisotopes SOC Ltd.

第10章 VERIFIED MARKET INTELLIGENCE

  • VERIFIED MARKET INTELLIGENCEについて
  • ダイナミックなデータの可視化
目次
Product Code: 38092

Nuclear Medicine Market Valuation - 2026-2032

The increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, respiratory disorders, neurological disorders, and metabolic conditions is a significant driver for the nuclear medicine market. Thus, the rising prevalence of chronic disorders surged the growth of market size surpassing USD 6.8 Billion in 2024 to reach a valuation of USD 12.99 Billion by 2032.

The adoption of nuclear medicine in the healthcare sector was at a nascent stage compared to traditional drug products. However, advancements in medical imaging technologies, radiopharmaceuticals, and the growing understanding of nuclear medicine's benefits have led to its increasing adoption. Thus, the increasing adoption of nuclear medicine in the healthcare sector enables the market to grow at a CAGR of 9.30% from 2026 to 2032.

Nuclear Medicine Market: Definition/ Overview

Nuclear medicine is a multidisciplinary field that utilizes radioactive materials, or radiopharmaceuticals, for the diagnosis and treatment of various diseases in areas such as neurology, cardiology, the endocrine system, the gastrointestinal system, and cancers. Radiopharmaceuticals contain a radioactive tracer that, when injected into the patient's body, emits gamma rays. These rays are captured by advanced imaging techniques like Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), enabling highly detailed images that aid in early detection, accurate diagnosis, and comprehensive examination of diseases, surpassing the capabilities of conventional imaging methods.

Recent advancements in radiopharmaceuticals have enhanced the ability to study micro-level physiological processes, such as cancer cell proliferation, myocardial perfusion in cardiac conditions, ventilation in severe pneumonia cases, and thyroid and parathyroid activity in hyperthyroidism. Nuclear medicine is increasingly used in research and development for next-generation therapies, including radiopharmaceutical conjugates with antibodies, biological drugs, and peptides. This enables targeted drug delivery, dose optimization, and the creation of innovative therapeutic solutions. As a result, nuclear medicine is not only a powerful diagnostic tool but also a key player in advancing therapeutic strategies across multiple medical fields.

How Does the Rising Incidence of Cancer and Cardiovascular Diseases Surge the Growth of the Nuclear Medicine Market?

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The American Heart Association reported that cardiovascular disease is the leading global cause of death, accounting for more than 17.9 million deaths per year in 2019. Technological advancements in radiopharmaceuticals and imaging equipment. According to the Verified Market Research, the Radiopharmaceuticals Market was valued at 6.05 billion in 2023 and is projected to reach USD 13.61 Billion by 2032, growing CAGR of 11.76%.

Increasing investment in nuclear medicine research and development. The U.S. Department of Energy's Office of Science budget for Nuclear Physics research was $713 million in fiscal year 2021. The European Commission allocated €1.38 billion for nuclear research and training activities under the Euratom Research and Training Programme 2021-2025. Growing awareness and acceptance of personalized medicine. According to the report of Verified Market Research the Personalized Medicine Market was valued at 130.23 Billion in 2023 and is projected to grow at 272.59 Billion by 2032, growing CAGR 10.67% from 2026 to 2032. A survey by the Personalized Medicine Coalition found that 73% of oncologists use personalized medicine testing for cancer patients.

Expanding applications of radioisotopes in molecular imaging. The U.S. Nuclear Regulatory Commission reported that approximately 50 million nuclear medicine procedures are performed each year in the United States. Increasing geriatric population and associated chronic diseases. The United Nations reported that the global population aged 65 and over is growing faster than all other age groups, expected to double to 1.5 billion by 2050. The WHO projects that by 2030, 1 in 6 people in the world will be aged 60 years or over, increasing the demand for diagnostic and therapeutic nuclear medicine procedures.

How does the High Cost of Nuclear Medicine Procedures and Equipment Impede the Growth of the Nuclear Medicine Market?

The high cost of nuclear medicine procedures and equipment hinders the growth of the nuclear medicine market. According to the American College of Radiology, the average cost of a PET/CT scan in the U.S. ranges from $1,250 to $1,650, which is prohibitively expensive for many patients. Stringent regulatory requirements. The U.S. Nuclear Regulatory Commission reported that it takes an average of 24 months to review and approve a new radiopharmaceutical. In Europe, the European Medicines Agency (EMA) approved only 3 new radiopharmaceuticals between 2018 and 2022, highlighting the rigorous approval process.

Short half-life of radiopharmaceuticals. The Society of Nuclear Medicine and Molecular Imaging noted that commonly used radioisotopes like Technetium-99m have a half-life of only 6 hours, complicating logistics and increasing costs. A study in the Journal of Nuclear Medicine found that up to 20% of prepared doses of short-lived radiopharmaceuticals go unused due to logistical challenges. Shortage of skilled nuclear medicine technologists. The U.S. Bureau of Labor Statistics projected a 5% growth in demand for nuclear medicine technologists from 2019 to 2029 but noted that the field is small, with only about 18,000 jobs in 2019. A survey by the American Society of Radiologic Technologists found that 4.7% of nuclear medicine technologist positions were vacant in 2019, indicating a shortage of qualified professionals.

Category-Wise Acumens

How the Diagnostic Imaging Technologies Foster the Growth of Diagnostic Nuclear Medicine Segment?

The diagnostic nuclear medicine segment dominates in the nuclear medicine market driven by advancements in diagnostic imaging technologies, such as the ability to capture high-resolution 3D images, faster device processing speeds, and increased automation. These improvements enhance the accuracy and efficiency of diagnosing various diseases, making nuclear medicine an essential tool in modern healthcare. Additionally, government interventions and the approval of numerous nuclear medicines for different disease treatments have accelerated the commercialization of these products, further expanding the segment's reach.

The development of a robust supply chain for radiopharmaceuticals and the availability of advanced infrastructure for the production and distribution of these medicines are also contributing to the segment's dominance. As a result, nuclear medicine is becoming more accessible, allowing healthcare providers to utilize cutting-edge diagnostic tools for early detection and precise treatment planning. These factors, coupled with growing healthcare investments and the demand for better diagnostic solutions, are expected to drive the market forward. The diagnostic nuclear medicine segment will continue to play a critical role in the healthcare landscape, improving patient outcomes and shaping the future of medical imaging and treatment.

How the Increasing Prevalence of Cancer Surge the Growth of Oncology Segment?

The oncology segment is set to dominate nuclear medicine driven by the increasing global burden of cancer. Changes in lifestyle, including unhealthy diets, smoking, and sedentary work habits, have significantly contributed to the rising incidence of cancer. Rapid urbanization has led to a larger population engaging in regular smoking, which remains a leading risk factor for various types of cancer. Additionally, sedentary lifestyles, characterized by minimal physical activity and a higher intake of processed and junk food, further exacerbate the cancer risk.

With cancer continuing to cause a significant number of deaths worldwide, there is a growing demand for more effective diagnostic and therapeutic tools. Nuclear medicine plays a critical role in oncology by offering highly advanced imaging techniques for early detection and precise diagnosis, which are crucial for improving treatment outcomes. Moreover, there has been a surge in investments aimed at developing novel radiopharmaceuticals and therapies specifically designed for cancer treatment. These advancements enable targeted treatment, improving patient outcomes while minimizing side effects.

Country/Region-wise Acumens

How Does the High Prevalence of Cancer and Cardiovascular Diseases Surge the Growth of the Nuclear Medicine Market in North America?

The increasing prevalence of cancer and cardiovascular disorders escalates the growth of nuclear medicine. According to the American Cancer Society, an estimated 1.9 million new cancer cases were diagnosed in the United States in 2021. The Centers for Disease Control and Prevention (CDC) reported that heart disease remains the leading cause of death in the U.S., accounting for about 659,000 deaths annually as of 2020. Strong research and development infrastructure The National Institutes of Health (NIH) budget for cancer research reached USD 6.56 Billion in fiscal year 2021, a significant portion of which supports nuclear medicine research. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) reported that over 20 million nuclear medicine procedures are performed each year in the United States.

Favorable Reimbursement Policies and Healthcare Spending. the Centers for Medicare & Medicaid Services (CMS) reported that national health spending in the U.S. grew 9.7% to $4.1 trillion in 2020, or $12,530 per person. A study published in the Journal of Nuclear Medicine found that Medicare reimbursement for PET scans increased by 14% between 2017 and 2020, encouraging wider adoption.

How does the Rapid Growth in Healthcare Infrastructure and Spending Foster the Growth of the Nuclear Medicine Market in Asia Pacific?

The growing healthcare infrastructure and high investment surge the growth of the nuclear medicine market in the Asia Pacific. According to the World Health Organization, healthcare spending in the Asia Pacific region was projected to grow at an annual rate of 7.1% between 2020 and 2024, outpacing the global average of 5.4%. China's healthcare expenditure reached 7.12 trillion yuan (approximately USD 1.1 Trillion) in 2020, a 10.2% increase from the previous year, as reported by the National Health Commission of China.

Increasing prevalence of cancer and cardiovascular diseases. The International Agency for Research on Cancer (IARC) estimated that in 2020, there were approximately 8.9 million new cancer cases in Asia, accounting for nearly half of the global cancer burden. The Asian Pacific Society of Cardiology reported that cardiovascular diseases accounted for 35% of all deaths in the Asia Pacific region in 2019, highlighting the need for advanced diagnostic and therapeutic options. Growing adoption of nuclear medicine technologies. The Indian nuclear medicine market was expected to grow at a CAGR of 10.5% between 2021 and 2026, driven by increasing government initiatives and rising awareness, as per a study published in the Journal of Nuclear Medicine Technology.

Competitive Landscape

The competitive landscape of the Nuclear Medicine Market is characterized by technological innovation, regulatory compliance, and a focus on providing high-quality, cost-effective services. Players must continuously invest in research and development, build strong partnerships, and adapt to evolving market trends to maintain a competitive edge.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the nuclear medicine market include:

  • Lantheus Medical Imaging, Inc.
  • Cardinal Health
  • Norgine B.V.
  • Nordion, Inc.
  • Bayer AG
  • Curium
  • Advanced Accelerator Applications
  • Bracco Diagnostic, Inc.
  • Jubilant Pharmova Limited
  • GE Healthcare (General Electric Company)

Latest Developments:

  • In April 2024, Curium announced the acquisition of EczacIbasI-Monrol Nuclear Product Co. This acquisition is expected to broaden its geographical reach, PET and SPECT infrastructure, and enable the development of cutting-edge radionuclide and radiopharmaceutical pipelines for diagnostic and therapeutic applications.
  • In February 2024, Curium reported that the Swissmedic had accepted their marketing authorization application for PYLCLARI, a novel (18F)-PSMA PET tracer, for evaluation.
  • In February 2024, Lantheus Holdings, Inc. announced the collaboration with the Consortium for Clarity in Alzheimer's Disease Research via Imaging (CLARiTI), which was financed by the National Institute on Aging.

Nuclear Medicine Market, By Category

  • Type:
  • Diagnostic Nuclear Medicine
  • PET Radiopharmaceuticals
  • SPECT Radiopharmaceuticals
  • Therapeutic Nuclear Medicine
  • Application:
  • Neurology
  • Cardiology
  • Oncology
  • End-Users:
  • Hospitals & Clinics
  • Diagnostic Centers
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL NUCLEAR MEDICINE MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Nuclear Medicine Market Geographical Analysis (CAGR %)
  • 3.6 Global Nuclear Medicine Market, By Type (USD Million)
  • 3.7 Global Nuclear Medicine Market, By Application (USD Million)
  • 3.8 Global Nuclear Medicine Market, By End-Users(USD Million)
  • 3.9 Future Market Opportunities
  • 3.10 Global Market Split
  • 3.11 Product Life Line

4 GLOBAL NUCLEAR MEDICINE MARKET OUTLOOK

  • 4.1 Global Nuclear Medicine Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL NUCLEAR MEDICINE MARKET BY TYPE

  • 5.1 Overview
  • 5.2 Diagnostic Nuclear Medicine
  • 5.3 PET Radiopharmaceuticals
  • 5.4 SPECT Radiopharmaceuticals
  • 5.5 Therapeutic Nuclear Medicine

6 GLOBAL NUCLEAR MEDICINE MARKET BY APPLICATION

  • 6.1 Overview
  • 6.2 Oncology
  • 6.3 Neurology
  • 6.4 Cardiology

7 GLOBAL NUCLEAR MEDICINE MARKET, BY END-USERS

  • 7.1 Overview
  • 7.2 Hospitals & Clinics
  • 7.3 Diagnostic Centers

8 GLOBAL NUCLEAR MEDICINE MARKET BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of Middle-East and Africa

9 GLOBAL NUCLEAR MEDICINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Developments
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 GE Healthcare
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Product Benchmarking
    • 10.1.4 Key Developments
    • 10.1.5 Winning Imperatives
    • 10.1.6 Current Focus & Strategies
    • 10.1.7 Threat from Competition
    • 10.1.8 SWOT Analysis
  • 10.2 Curium Pharma
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Product Benchmarking
    • 10.2.4 Key Developments
    • 10.2.5 Winning Imperatives
    • 10.2.6 Current Focus & Strategies
    • 10.2.7 Threat from Competition
    • 10.2.8 SWOT Analysis
  • 10.3 Novartis
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Product Benchmarking
    • 10.3.4 Key Developments
    • 10.3.5 Winning Imperatives
    • 10.3.6 Current Focus & Strategies
    • 10.3.7 Threat from Competition
    • 10.3.8 SWOT Analysis
  • 10.4 Cardinal Health
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Product Benchmarking
    • 10.4.4 Key Developments
    • 10.4.5 Winning Imperatives
    • 10.4.6 Current Focus & Strategies
    • 10.4.7 Threat from Competition
    • 10.4.8 SWOT Analysis
  • 10.5 Lantheus Medical Imaging
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Product Benchmarking
    • 10.5.4 Key Developments
    • 10.5.5 Winning Imperatives
    • 10.5.6 Current Focus & Strategies
    • 10.5.7 Threat from Competition
    • 10.5.8 SWOT Analysis
  • 10.6 Jubilant Life Sciences Ltd
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Product Benchmarking
    • 10.6.4 Key Developments
    • 10.6.5 Winning Imperatives
    • 10.6.6 Current Focus & Strategies
    • 10.6.7 Threat from Competition
    • 10.6.8 SWOT Analysis
  • 10.7 Nordion Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Product Benchmarking
    • 10.7.4 Key Developments
    • 10.7.5 Winning Imperatives
    • 10.7.6 Current Focus & Strategies
    • 10.7.7 Threat from Competition
    • 10.7.8 SWOT Analysis
  • 10.8 Bracco Imaging S.P.A
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Product Benchmarking
    • 10.8.4 Key Developments
    • 10.8.5 Winning Imperatives
    • 10.8.6 Current Focus & Strategies
    • 10.8.7 Threat from Competition
    • 10.8.8 SWOT Analysis
  • 10.9 The Institute for Radioelements (IRE)
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Product Benchmarking
    • 10.9.4 Key Developments
    • 10.9.5 Winning Imperatives
    • 10.9.6 Current Focus & Strategies
    • 10.9.7 Threat from Competition
    • 10.9.8 SWOT Analysis
  • 10.10 NTP Radioisotopes SOC Ltd.
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Product Benchmarking
    • 10.10.4 Key Developments
    • 10.10.5 Winning Imperatives
    • 10.10.6 Current Focus & Strategies
    • 10.10.7 Threat from Competition
    • 10.10.8 SWOT Analysis

10 VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization